Mechanisms of mutations in myeloproliferative neoplasms

Best Practice and Research: Clinical Haematology

Volumn 22, Issue 4, 2009, Pages 489-494

  Levine, Ross L ^a  

^a Leukemia Service   (United States)

Author keywords

essential thrombocytosis; JAK2; MPL; MPN; mutations; myelofibrosis; myeloproliferative neoplasms; polycythaemia vera; TET2

Indexed keywords

BCR ABL PROTEIN; IMATINIB; JANUS KINASE 2; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR;

AMINO ACID SUBSTITUTION; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; EOSINOPHILIC LEUKEMIA; GENETIC PREDISPOSITION; HUMAN; MISSENSE MUTATION; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PATHOGENESIS; POINT MUTATION; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; SYSTEMIC MASTOCYTOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ANIMALS; HUMANS; JANUS KINASE 2; MUTATION; MYELOPROLIFERATIVE DISORDERS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 71749114664     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2009.08.006     Document Type: Review

References (20)

1. Sawyers C.L., Hochhaus A., Feldman E., et al. Imatinib induces hematologic and cytogenic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99 (2002) 3530-3539
2. Shah N.P., Lee F.Y., Luo R., et al. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 108 (2006) 286-291
3. Cools J., DeAngelo D.J., Gotlib J., et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348 (2003) 1201-1214
4. Gotlib J., Cools J., Malone III J.M., et al. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood 103 (2004) 2879-2891
5. James C., Ugo V., Le Couedic J.P., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434 (2005) 1144-1148
6. Levine R.L., Wadleigh M., Cools J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7 (2005) 387-397
7. Baxter E.J., Scott L.M., Campbell P.J., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365 (2005) 1054-1061
8. Kralovics R., Passamonti F., Buser A.S., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352 (2005) 1779-1790
9. Dusa A., Staerk J., Elliott J., et al. Substitution of pseudokinase domain residue Val-617 by large non-polar amino acids causes activation of JAK2. J Biol Chem 283 (2008) 12941-12948
10. Wernig G., Mercher T., Okabe R., et al. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 107 (2006) 4274-4281
11. Tiedt R., Hao-Shen H., Sobas M.A., et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 111 (2008) 3931-3940
12. Scott L.M., Tong W., Levine R.L., et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356 (2007) 459-468
13. Pikman Y., Lee B.H., Mercher T., et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 3 (2006) e270
14. Pardanani A.D., Levine R.L., Lasho T., et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 108 (2006) 3472-3476
15. Delhommeau F., Dupont S., James C., et al. Mutation in TET2 in myeloid cancers. N Engl J Med 360 (2009) 2289-2301
16. Abdel-Wahab O., Mullally A., Hedvat C., et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 114 (2009) 144-147
17. Levine R.L., Pardanani A., Tefferi A., et al. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 7 (2007) 673-683
18. Olcaydu D., Harutyunyan A., Jäger R., et al. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet 41 (2009) 450-454
19. Jones A.V., Chase A., Silver R.T., et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet 41 4 (2009) 446-449
20. Kilpivaara O., Mukherjee S., Schram A.M., et al. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet 41 (2009) 455-459